Opinion|Videos|July 9, 2024
Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
Advertisement
Related to this article
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
4
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
5